Unknown

Dataset Information

0

Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide.


ABSTRACT: Carfilzomib-lenalidomide-dexamethasone (KRd) therapy has yielded promising results in patients with newly diagnosed multiple myeloma (NDMM). Cereblon (CRBN) is the direct molecular target of lenalidomide and genetic polymorphisms in CRBN have been associated with lenalidomide efficacy. In this study, we assessed the correlation of five single nucleotide variants (SNVs) in the CRBN gene with clinical response and outcomes in patients with NDMM administered KRd therapy with lenalidomide maintenance, achieving favorable trial endpoints in a prospective Phase II study (NCT01402284). Of the observed SNVs, no associations with KRd therapy response were found in this patient cohort, although strong trends in hypoalbuminemia grade and hyperbilirubinemia grade emerged across the CRBN rs1672753 genotype (P?=?0.0008) and the rs1714327 genotype (P?=?0.0010), respectively. Our results do not provide conclusive support for the predictive utility of CRBN gene polymorphisms as potential biomarkers of clinical response to lenalidomide-based therapy in our patient population. However, these findings remain to be validated in prospective studies using larger patient populations.

SUBMITTER: Huang PA 

PROVIDER: S-EPMC6795854 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide.

Huang Phoebe A PA   Beedie Shaunna L SL   Chau Cindy H CH   Venzon David J DJ   Gere Sheryl S   Kazandjian Dickran D   Korde Neha N   Mailankody Sham S   Landgren Ola O   Figg William D WD  

Scientific reports 20191016 1


Carfilzomib-lenalidomide-dexamethasone (KRd) therapy has yielded promising results in patients with newly diagnosed multiple myeloma (NDMM). Cereblon (CRBN) is the direct molecular target of lenalidomide and genetic polymorphisms in CRBN have been associated with lenalidomide efficacy. In this study, we assessed the correlation of five single nucleotide variants (SNVs) in the CRBN gene with clinical response and outcomes in patients with NDMM administered KRd therapy with lenalidomide maintenanc  ...[more]

Similar Datasets

| S-EPMC7893409 | biostudies-literature
| S-EPMC6037886 | biostudies-other
| S-EPMC10143497 | biostudies-literature
| S-EPMC7156787 | biostudies-literature
| S-EPMC5334380 | biostudies-literature
| S-EPMC4070318 | biostudies-literature
| S-EPMC5808078 | biostudies-other
| S-EPMC5908898 | biostudies-literature
| S-EPMC6357961 | biostudies-literature
| S-EPMC8569411 | biostudies-literature